Financial Performance - Revenue for the year ended December 31, 2025, was RMB 47,404 thousand, a decrease of 48.3% from RMB 91,885 thousand in 2024[2] - Gross profit for 2025 was RMB 4,264 thousand, with a gross margin of 9.0%, compared to RMB 6,485 thousand and a gross margin of 7.1% in 2024[3] - The net loss for the year was RMB 36,016 thousand, slightly increasing from RMB 36,005 thousand in 2024[4] - Basic and diluted loss per share for 2025 was RMB 0.13, compared to RMB 0.05 in 2024[4] - The group reported a total loss before tax of RMB 35,963,000 for the year ended December 31, 2025, compared to a loss of RMB 35,958,000 in 2024[22] - The pre-tax loss for 2025 was RMB 43,663,000, compared to RMB 81,503,000 in 2024, indicating a significant reduction in losses[26] - The net loss for the reporting period was RMB 36.0 million, reflecting the factors mentioned above[63] Assets and Liabilities - Total assets as of December 31, 2025, were RMB 146,686 thousand, an increase from RMB 137,470 thousand in 2024[5] - Total liabilities decreased to RMB 87,023 thousand in 2025 from RMB 95,077 thousand in 2024[6] - Cash and cash equivalents increased significantly to RMB 27,074 thousand in 2025 from RMB 2,299 thousand in 2024[5] - Inventory decreased to RMB 17,477 thousand in 2025 from RMB 30,713 thousand in 2024[5] - Trade receivables also decreased to RMB 6,227 thousand in 2025 from RMB 24,645 thousand in 2024[5] - The group’s liabilities totaled RMB (87,023,000) as of December 31, 2025, with segment liabilities of RMB (36,048,000) for kitchenware and RMB (578,000) for health-related products[24] - The company's net current assets as of December 31, 2025, were RMB 42.3 million, an increase from RMB 29.3 million as of December 31, 2024[77] Revenue Breakdown - Revenue from kitchenware products in 2025 was RMB 34,507,000, down from RMB 46,821,000 in 2024, representing a decline of 26%[17] - Revenue from health-related products dropped significantly from RMB 45,064,000 in 2024 to RMB 12,897,000 in 2025, a decrease of 71%[17] - Revenue from health-related products accounted for 27.2% of total revenue, amounting to RMB 12.9 million, down from 49.1% or RMB 45.1 million in the previous year[43] - Direct sales from consignment stores decreased by 23.6% to RMB 11.0 million, primarily due to reduced consumer spending amid economic challenges[48] - Sales revenue from corporate clients dropped by 83.3% to RMB 0.1 million, attributed to a decline in orders from Chinese property developers[49] - Direct sales revenue from the television platform decreased by 71.4% to RMB 1.0 million, primarily due to reduced consumer spending[50] - Online platform sales revenue fell by 30.4% to RMB 5.5 million, attributed to poor economic conditions leading to decreased consumer expenditure[51] - Revenue from physical sales locations dropped by 54.4% to RMB 29.8 million, mainly due to adjustments and restructuring of health-related product offerings[52] Expenses and Costs - The group incurred a cost of goods sold of RMB 43,663,000 in 2025, which included inventory write-downs of RMB 6,231,000[26] - Selling and distribution expenses rose by 8.6% to RMB 18.9 million, mainly due to increased promotional and advertising costs[56] - Administrative expenses increased by 6.2% to RMB 15.4 million, primarily due to higher share issuance costs[57] - Research and development expenses decreased by 1.7% to RMB 5.8 million, attributed to cost control measures[58] - Financial costs decreased by 26.2% to RMB 3.1 million, mainly due to the repayment of loans[60] Share Capital and Rights Issue - The company proposed to increase its authorized share capital from HKD 100 million to HKD 150 million by issuing an additional 200,000,000 shares at a nominal value of HKD 0.25 each[69] - The subscription price for the rights issue was set at HKD 0.25 per share, with the market price on the announcement date being HKD 0.158 per share[69] - A total of 208,370,000 unclaimed rights shares were successfully placed at the subscription price of HKD 0.25 per share, with one subscriber acquiring 100,000,000 shares, making them a major shareholder[73] - The total number of shares issued under the rights issue was 242,837,879 shares, with a total nominal value of approximately HKD 60.7 million[74] - The net proceeds from the rights issue, after deducting related expenses, amounted to approximately HKD 58.9 million, equivalent to a net price of about HKD 0.24 per rights share[74] Corporate Governance and Future Plans - The company established a wholly-owned subsidiary, Shenzhen Can Dong Health Technology Co., Ltd., focusing on health data analysis and intelligent services[40] - Future plans include continued investment in digitalization, artificial intelligence, and biotechnology to enhance service capabilities and competitiveness[41] - The company aims to build a comprehensive healthcare service ecosystem, focusing on medical care, digital health, and health management services[39] - The audit committee reviewed the financial reporting system and confirmed that the consolidated financial statements were prepared in accordance with applicable standards[104] - No significant events requiring adjustments or disclosures in the financial statements were identified after the reporting period[106] Employment and Staff - The company employed 52 staff members as of December 31, 2025, down from 69 employees as of December 31, 2024[87]
智慧健康科技(01715) - 2025 - 年度业绩